Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis.

Humans Ustekinumab / therapeutic use Glomerulonephritis / drug therapy Male Female Middle Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy Antibodies, Antineutrophil Cytoplasmic / immunology CD8-Positive T-Lymphocytes / immunology CD4-Positive T-Lymphocytes / immunology Interleukin-12 / metabolism Aged Adult Kidney / pathology Cyclophosphamide / therapeutic use Gene Expression Profiling Immunosuppressive Agents / therapeutic use Single-Cell Analysis

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 Sep 2024
Historique:
received: 14 05 2024
accepted: 11 09 2024
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 19 9 2024
Statut: epublish

Résumé

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (GN). To date, treatment of most patients with ANCA-GN relies on non-specific immunosuppressive agents, which may have serious adverse effects and be only partially effective. Here, using spatial and single-cell transcriptome analysis, we characterize inflammatory niches in kidney samples from 34 patients with ANCA-GN and identify proinflammatory, cytokine-producing CD4

Identifiants

DOI: 10.1038/s41467-024-52525-w PMID: 39300109
pubmed: 39300109
doi: 10.1038/s41467-024-52525-w
pii: 10.1038/s41467-024-52525-w
doi:

Substances chimiques

Ustekinumab FU77B4U5Z0
Antibodies, Antineutrophil Cytoplasmic 0
Interleukin-12 187348-17-0
Cyclophosphamide 8N3DW7272P
Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8220

Subventions

Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB1192
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB1192
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB1192

Informations de copyright

© 2024. The Author(s).

Références

Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Prim. 6, 71 (2020).
pubmed: 32855422 doi: 10.1038/s41572-020-0204-y
Anders, H.-J., Kitching, A. R., Leung, N. & Romagnani, P. Glomerulonephritis. Immunopathogenesis and immunotherapy. Nat. Rev. Immunol. 23, 453–471 (2023).
pubmed: 36635359 doi: 10.1038/s41577-022-00816-y
Kurts, C., Panzer, U., Anders, H.-J. & Rees, A. J. The immune system and kidney disease. Basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738–753 (2013).
pubmed: 24037418 doi: 10.1038/nri3523
Wilde, B., van Paassen, P., Witzke, O. & Tervaert, J. W. C. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 79, 599–612 (2011).
pubmed: 21150876 doi: 10.1038/ki.2010.472
Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771–1780 (2014).
pubmed: 25372085 doi: 10.1056/NEJMoa1404231
Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417–427 (2013).
pubmed: 23902481 pmcid: 5953195 doi: 10.1056/NEJMoa1213277
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
pubmed: 20647199 pmcid: 3137658 doi: 10.1056/NEJMoa0909905
Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599–609 (2021).
pubmed: 33596356 doi: 10.1056/NEJMoa2023386
Lyons, P. A. et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann. Rheum. Dis. 69, 1208–1213 (2010).
pubmed: 19815495 doi: 10.1136/ard.2009.108043
Grayson, P. C. et al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 67, 1922–1932 (2015).
pubmed: 25891759 pmcid: 4485551 doi: 10.1002/art.39153
Banos, A. et al. The genomic landscape of ANCA-associated vasculitis. Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus. Front. Immunol. 14, 1072598 (2023).
pubmed: 37051253 pmcid: 10083368 doi: 10.3389/fimmu.2023.1072598
Nishide, M. et al. Single-cell multi-omics analysis identifies two distinct phenotypes of newly-onset microscopic polyangiitis. Nat. Commun. 14, 5789 (2023).
pubmed: 37821442 pmcid: 10567716 doi: 10.1038/s41467-023-41328-0
O’Reilly, V. P. et al. Urinary soluble CD163 in active renal vasculitis. J. Am. Soc. Nephrol. 27, 2906–2916 (2016).
pubmed: 26940094 pmcid: 5004645 doi: 10.1681/ASN.2015050511
Krebs, C. F. et al. Pathogen-induced tissue-resident memory TH17 (TRM17) cells amplify autoimmune kidney disease. Sci. Immunol. 5, eaba4163 (2020).
pubmed: 32769171 doi: 10.1126/sciimmunol.aba4163
Paust, H.-J. et al. CD4+ T cells produce GM-CSF and drive immune-mediated glomerular disease by licensing monocyte-derived cells to produce MMP12. Sci. Transl. Med. 15, eadd6137 (2023).
pubmed: 36921033 doi: 10.1126/scitranslmed.add6137
Brix, S. R. et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 94, 1177–1188 (2018).
pubmed: 30385041 doi: 10.1016/j.kint.2018.07.020
Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585–594 (2023).
pubmed: 37468583 pmcid: 10356613 doi: 10.1038/s41586-023-05769-3
Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484, 514–518 (2012).
pubmed: 22466287 doi: 10.1038/nature10957
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
pubmed: 20647198 doi: 10.1056/NEJMoa0909169
Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020).
pubmed: 32053298 pmcid: 7325726 doi: 10.1056/NEJMoa1803537
Tan, J. A. et al. Mortality in ANCA-associated vasculitis. A meta-analysis of observational studies. Ann. Rheum. Dis. 76, 1566–1574 (2017).
pubmed: 28468793 doi: 10.1136/annrheumdis-2016-210942
Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488–494 (2011).
pubmed: 21109517 doi: 10.1136/ard.2010.137778
Sánchez Álamo, B. et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 38, 1655–1665 (2023).
pubmed: 36617233 doi: 10.1093/ndt/gfac320
Heckmann, M. et al. The Wegener’s granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann. Rheum. Dis. 67, 972–979 (2008).
pubmed: 17967832 doi: 10.1136/ard.2007.077693
Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).
pubmed: 22808956 pmcid: 3773907 doi: 10.1056/NEJMoa1108735
Wang, H.-Y. et al. Risk HLA class II alleles and amino acid residues in myeloperoxidase-ANCA-associated vasculitis. Kidney Int. 96, 1010–1019 (2019).
pubmed: 31471160 doi: 10.1016/j.kint.2019.06.015
McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586 (2010).
pubmed: 20400961 pmcid: 3504359 doi: 10.1038/nm.2130
Abdulahad, W. H., Kallenberg, C. G. M., Limburg, P. C. & Stegeman, C. A. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2830–2838 (2009).
pubmed: 19714581 doi: 10.1002/art.24747
Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209–2217 (2010).
pubmed: 20100727 doi: 10.1093/ndt/gfp783
Schmitt, W. H. et al. Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG). An open study in 15 patients. Kidney Int. 65, 1440–1448 (2004).
pubmed: 15086487 doi: 10.1111/j.1523-1755.2004.00534.x
Griffiths, C. E. M. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
pubmed: 20071701 doi: 10.1056/NEJMoa0810652
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis. Randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
pubmed: 19217154 doi: 10.1016/S0140-6736(09)60140-9
Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 375, 1946–1960 (2016).
pubmed: 27959607 doi: 10.1056/NEJMoa1602773
Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).
pubmed: 31553833 doi: 10.1056/NEJMoa1900750
Jin, Y. et al. Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis. Arthritis Care Res. 74, 1792–1805 (2022).
doi: 10.1002/acr.24630
Papp, K. et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J. Drugs Dermatol. 14, 706–714 (2015).
pubmed: 26151787
Ghosh, S. et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn’s disease. An integrated analysis of phase II/III clinical development programs. Drug Saf. 42, 751–768 (2019).
pubmed: 30739254 pmcid: 6520311 doi: 10.1007/s40264-019-00797-3
Ritchlin, C. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy. 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73, 990–999 (2014).
pubmed: 24482301 doi: 10.1136/annrheumdis-2013-204655
McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis. 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780–789 (2013).
pubmed: 23769296 doi: 10.1016/S0140-6736(13)60594-2
van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus. Results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392, 1330–1339 (2018).
pubmed: 30249507 doi: 10.1016/S0140-6736(18)32167-6
Li, H. et al. IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. J. Clin. Investig. 131, e142428 (2021).
pubmed: 33956666 pmcid: 8203450 doi: 10.1172/JCI142428
Gan, P.-Y. et al. Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis. Kidney Int. 96, 1121–1133 (2019).
pubmed: 31443998 doi: 10.1016/j.kint.2019.05.012
Kitching, A. R., Holdsworth, S. R. & Tipping, P. G. IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J. Am. Soc. Nephrol. 10, 752–759 (1999).
pubmed: 10203359 doi: 10.1681/ASN.V104752
Paust, H.-J. et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20, 969–979 (2009).
pubmed: 19339380 pmcid: 2678032 doi: 10.1681/ASN.2008050556
Schreiber, A. et al. Neutrophil gelatinase-associated lipocalin protects from ANCA-induced GN by inhibiting TH17 immunity. J. Am. Soc. Nephrol. 31, 1569–1584 (2020).
pubmed: 32487561 pmcid: 7350985 doi: 10.1681/ASN.2019090879
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY. Large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Palla, G. et al. Squidpy. A scalable framework for spatial omics analysis. Nat. Methods 19, 171–178 (2022).
pubmed: 35102346 pmcid: 8828470 doi: 10.1038/s41592-021-01358-2
Kang, J. B. et al. Efficient and precise single-cell reference atlas mapping with Symphony. Nat. Commun. 12, 5890 (2021).
pubmed: 34620862 pmcid: 8497570 doi: 10.1038/s41467-021-25957-x
Büttner, M., Ostner, J., Müller, C. L., Theis, F. J. & Schubert, B. scCODA is a Bayesian model for compositional single-cell data analysis. Nat. Commun. 12, 6876 (2021).
pubmed: 34824236 pmcid: 8616929 doi: 10.1038/s41467-021-27150-6
Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler. An R package for comparing biological themes among gene clusters. Omics J. Integr. Biol. 16, 284–287 (2012).
doi: 10.1089/omi.2011.0118
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA. Gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Gayoso, A. et al. Joint probabilistic modeling of single-cell multi-omic data with totalVI. Nat. Methods 18, 272–282 (2021).
pubmed: 33589839 pmcid: 7954949 doi: 10.1038/s41592-020-01050-x
Stewart, B. J. et al. Spatiotemporal immune zonation of the human kidney. Science 365, 1461–1466 (2019).
pubmed: 31604275 pmcid: 7343525 doi: 10.1126/science.aat5031
Khatri, R., Machart, P. & Bonn, S. DISSECT. Deep semi-supervised consistency regularization for accurate cell type fraction and gene expression estimation. Genome Biol. 25, 112 (2024).
pubmed: 38689377 pmcid: 11061925 doi: 10.1186/s13059-024-03251-5
Mendez, D. et al. ChEMBL. Towards direct deposition of bioassay data. Nucleic Acids Res. 47, D930–D940 (2019).
pubmed: 30398643 doi: 10.1093/nar/gky1075
Freshour, S. L. et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 49, D1144–D1151 (2021).
pubmed: 33237278 doi: 10.1093/nar/gkaa1084
Kanemaru, K. et al. Spatially resolved multiomics of human cardiac niches. Nature 619, 801–810 (2023).
pubmed: 37438528 pmcid: 10371870 doi: 10.1038/s41586-023-06311-1

Auteurs

Jonas Engesser (J)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Robin Khatri (R)

Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Medical Systems Biology, Center for Biomedical AI, Center for Molecular Neurobiology Hamburg, Hamburg, Germany.
ORCID: 0009-0006-5311-1718

Darius P Schaub (DP)

Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Medical Systems Biology, Center for Biomedical AI, Center for Molecular Neurobiology Hamburg, Hamburg, Germany.

Yu Zhao (Y)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Medical Systems Biology, Center for Biomedical AI, Center for Molecular Neurobiology Hamburg, Hamburg, Germany.
ORCID: 0000-0003-2632-7530

Hans-Joachim Paust (HJ)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Zeba Sultana (Z)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Medical Systems Biology, Center for Biomedical AI, Center for Molecular Neurobiology Hamburg, Hamburg, Germany.
ORCID: 0000-0001-6610-9955

Nariaki Asada (N)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jan-Hendrik Riedel (JH)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Varshi Sivayoganathan (V)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Anett Peters (A)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Anna Kaffke (A)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Saskia-Larissa Jauch-Speer (SL)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0002-6739-3051

Thiago Goldbeck-Strieder (T)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Victor G Puelles (VG)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ulrich O Wenzel (UO)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0002-0116-255X

Oliver M Steinmetz (OM)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0001-5142-328X

Elion Hoxha (E)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jan-Eric Turner (JE)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0002-1677-5455

Hans-Willi Mittrücker (HW)

Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute for Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0001-6166-4191

Thorsten Wiech (T)

Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Pathology, Division of Nephropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0003-4053-1474

Tobias B Huber (TB)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID: 0000-0001-7175-5062

Stefan Bonn (S)

Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. s.bonn@uke.de.
Institute of Medical Systems Biology, Center for Biomedical AI, Center for Molecular Neurobiology Hamburg, Hamburg, Germany. s.bonn@uke.de.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. s.bonn@uke.de.

Christian F Krebs (CF)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. c.krebs@uke.de.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. c.krebs@uke.de.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. c.krebs@uke.de.
ORCID: 0000-0003-2739-5578

Ulf Panzer (U)

Department of Medicine III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. panzer@uke.de.
Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. panzer@uke.de.
Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. panzer@uke.de.
ORCID: 0000-0001-9449-0722

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Ustékinumab › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Néphrite › Glomérulonéphrite › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Anticorps anti-cytoplasme des polynucléaires neutrophiles › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-12 › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Cyclophosphamide › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Immune profiling-based targeting of pathogenic...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Analyse sur cellule unique › Immune profiling-based targeting of pathogenic...